Novo, the Danish obesity drugs pioneer, is down 20% from its peak in January and trades at 15 times forward price-to-earnings, below its five-year average of 26. He believes the market is underestimating the strength of the franchise and the industry’s long term-growth potential as treatments become more affordable.







